-

07:29:35 PM

LXRX Stock News

LXRX - Lexicon Pharmaceuticals Inc

08/05/22 4:59 PM

Nasdaq : LXRX

offering

Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001 (the “ Common Stock ”), pursuant to the full exercise of the

RHEA-AI

neutral

08/02/22 4:01 PM

Nasdaq : LXRX

earnings

Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neuropathic Pain Conference Call and Webcast at

RHEA-AI

neutral

07/29/22 8:00 AM

Nasdaq : LXRX

conferencesearnings

Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m.

RHEA-AI

neutral

07/28/22 7:00 AM

Nasdaq : LXRX

offering

Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the “ Common Stock ”). The shares of

RHEA-AI

neutral

07/27/22 4:01 PM

Nasdaq : LXRX

offering

Lexicon Announces Proposed Public Offering Of Common Stock

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the “

RHEA-AI

neutral

07/27/22 7:59 AM

Nasdaq : LXRX

Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for

RHEA-AI

very negative

06/29/22 4:01 PM

Nasdaq : LXRX

clinical trial

Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

RHEA-AI

neutral

06/01/22 8:00 AM

Nasdaq : LXRX

conferences

Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET. A webcast of the event

RHEA-AI

neutral

05/31/22 8:00 AM

Nasdaq : LXRX

Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the treatment of

RHEA-AI

neutral

05/05/22 6:00 AM

Nasdaq : LXRX

earnings

Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. “We plan to resubmit our

RHEA-AI

very negative

1 2 3 4 5 6 7 Next

LXRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.lexpharma.com
Security nameLexicon Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees78
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Lexicon Pharmaceuticals Inc

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications.